BiotechTube

VX-670

Phase 2Recruiting
0 views this week 0 watching⚡ Active
Interest: 42/100
42
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Myotonic Dystrophy Type 1 (DM1)

Conditions

Myotonic Dystrophy Type 1 (DM1)

Trial Timeline

Apr 28, 2025 → Jan 30, 2029

NCT ID
NCT06926621

About VX-670

VX-670 is a phase 2 stage product being developed by Vertex Pharmaceuticals for Myotonic Dystrophy Type 1 (DM1). The current trial status is recruiting. This product is registered under clinical trial identifier NCT06926621. Target conditions include Myotonic Dystrophy Type 1 (DM1).

What happened to similar drugs?

0 of 2 similar drugs in Myotonic Dystrophy Type 1 (DM1) were approved

Approved (0) Terminated (0) Active (2)
🔄Del-desiran (AOC 1001)Avidity BiosciencesPhase 3
🔄DYNE-101 + PlaceboDyne TherapeuticsPhase 3

Hype Score Breakdown

Clinical
12
Activity
15
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT06926621Phase 2Recruiting

Competing Products

16 competing products in Myotonic Dystrophy Type 1 (DM1)

See all competitors
ProductCompanyStageHype Score
TideglusibAMO PharmaPre-clinical
20
TideglusibAMO PharmaPhase 2
25
Tideglusib + PlaceboAMO PharmaPhase 2/3
28
TideglusibAMO PharmaPhase 2/3
35
VX-670 + PlaceboVertex PharmaceuticalsPhase 1/2
39
SAR446268SanofiPhase 1/2
39
rhIGF-I/rhIGFBP-3 + placeboInsmedPhase 2
32
IONIS-DMPKRx + PlaceboIonis PharmaceuticalsPhase 1/2
29
Del-desiran (AOC 1001)Avidity BiosciencesPhase 3
44
ARO-DM1 Intravenous (IV) Infusion + Placebo Intravenous (IV) Infusion + ARO-DM1 subcutaneous (SC) injection + Placebo Subcutaneous (SC) InjectionArrowhead PharmaceuticalsPhase 1/2
36
DYNE-101 + PlaceboDyne TherapeuticsPhase 3
41
DYNE-101 + PlaceboDyne TherapeuticsPhase 1/2
33
Pitolisant Oral Tablet + Placebo oral tabletHarmony BiosciencesPhase 2
29
PGN-EDODM1PepGenPhase 2
32
PGN-EDODM1PepGenPhase 2
32
PGN-EDODM1 for infusionPepGenPhase 1
19